top of page

Why Emocog

We create technology that helps sustain brain health

Dementia affects about 10% of the senior population and progresses over a decade. The stage of memory decline before dementia is called Mild Cognitive Impairment (MCI) and progresses overhalf a decade. The prevalence rate is about 25%.

Emocog develops solutions for each stage of dementia, including Cogthera, a cognitive improving digital therapeutics for MCI.

Research

Technology based on world-class scientific results

The results of 20 years of research was published in 5 leading *SCI-indexed journals on brain disease.

*Science Citation Index (SCI): renowned journals carefully selected based on strict criteria among science and technology journals

Solution 1

Emocog builds an ecosystem to care for the entire journey from screening, diagnosis and treatment of dementia.

To overcome the physical constraints of not being able to care for every patient every day, we propose innovative solutions utilizing digital technology.

*Digital treatments and medical applications(DiGA) are virtual medical products that are available as apps for mobile devices or as browser applications. Cogthera DE can quickly enter the market and receive very high insurance rates through these process.

Emocog’s Digital Dementia Solutions

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

MemoryPick    Mobile Cognitive Assessment Service to Screen for Dementia Risk

LAUNCH

PRODUCT
APPROVAL

CLINICAL
EVALUATION

PERFORMANCE
TEST

DETAILED
DESIGN

PROTOTYPE
& TEST

PROOF OF
CONCEPT

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

Cogthera KR    Digital Therapeutics for MCI

LAUNCH

PRODUCT
APPROVAL

CLINICAL
EVALUATION

DEVELOPMENT
& PROGRAMING

CONCEPTION

REQUIREMENT
ANALYSIS

(DiGA* fast track process in Germany)

Cogthera DE    German-optimized Digital Therapeutics for MCI

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

PDT    Parkinson’s Disease Diagnostic Assistant Software

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

AlzVoice    Memory and Attention Assessment Service based on Verbal Conversation

It is a responsive web-based online test that can be performed on various devices and operating systems through a QR or a URL.

The test takes only about 5 minutes, providing comfortable and easy-to-use content based on simple words and shapes.

Improve the accuracy of the results through large-scale compliance data by accounting for differences in cognitive function based on age, education, gender, etc.

MemoryPick

MemoryPick is a digital screening tool that helps users detect early signs of cognitive decline. It evaluates memory and executive function, which are the first cognitive areas to decline due to dementia, as well as subjective cognitive decline and depression.

At the end of the test, it shows an instant results report representing the user’s brain health. Based on the results, it recommends memory strategies to help daily life and lifestyle habits to keep the brain healthy.

Mobile cognitive assessment service to help screen for dementia risk

1

Conversation-based interface using vocal cues, made for the convenience of patients with early cognitive decline.

After accurate assessments of the patient’s cognitive ability, training contents are automatically generated via AI technology, providing personalized training with difficulty adjustments.

Accessible anytime and anywhere, free from restraints of professional presence, location, and time.

Cogthera

Cogthera constantly monitors patients’ cognitive functions and provides personalized cognitive training to strengthen the neural networks and increase the *cognitive reserve.

It was designated as an Innovative Medical Device by MFDS and became the first cognitive intervention treatment software for MCI to be designated as an Innovative Medical Device in Korea.

Software as a Medical Device to improve Mild Cognitive Impairment

2

In addition to clinical trials in Korea, Cogthera is simultaneously pursuing German DiGA (Digital treatment and medical applications). DiGA is a fast-track system by German regulatory, BfArM, with an advantage of fast market entry and high reimbursement rate.

DiGA Fast Track

Solution 2

Digital Solutions for Learning Disorder

With Happymind, the developer of CAT, which has a high market share in Korea, we are rapidly growing by sharing development technology, know-how, and networks accumulated over the years.

Happymind evaluates problems related to learning disorders such as attention deficit, poor reading skills and poor math skills, and provides solutions to them.

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

CAT    Comprehensive Attention Test for children and adults

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

NeuLearn    Application using neuroscience-based learning techniques to help memorize English words

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

Dyscalculia Treatment Program   Program to treat those with mathematical and calculational difficulties

LAUNCH

DATA COLLECTION
& ANALYSIS

DETAILED
DESIGN

PROTOTYPE
& TEST

CONCEPT
DEVELOPMENT

DEFINE
THE BRIEF

sCAT    Short version of CAT for institutions

LAUNCH

DATA COLLECTION